Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5195 ARTÍCULOS , VIENDO DEL 2581 AL 2595

[Direct and indirect neurological manifestations of COVID-19]

Gromova OA, Torshin IY, Semenov VA, Putilina MV, Chuchalin AG.

Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(11):11-21. doi: 10.17116/jnevro202012011111.

A Case of Pregabalin-Induced Parkinsonism

Ari BC, Domac FM, Kenangil GO.

Neurol India. 2020 Nov-Dec;68(6):1469-1471. doi: 10.4103/0028-3886.304071.

A Specific Diplotype H1j/H2 of the MAPT Gene Could Be Responsible for Parkinson's Disease with Dementia

Smaili I, Hajjaj I, Razine R, Tibar H, Salmi A, Bouslam N, Moussa A, Regragui W, Bouhouche A.

Case Rep Genet. 2020 Dec 3;2020:8813344. doi: 10.1155/2020/8813344. eCollection 2020.

Toward a Computational Neuropsychology of Cognitive Flexibility

Steinke A, Kopp B.

Brain Sci. 2020 Dec 17;10(12):1000. doi: 10.3390/brainsci10121000.

How do adenosine A(2A) receptors regulate motor function?

Mori A.

Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S13-S20. doi: 10.1016/j.parkreldis.2020.09.025. Epub 2020 Dec 19.

Can adenosine A(2A) receptor antagonists modify motor behavior and dyskinesia in experimental models of Parkinson's disease?

Kanda T, Jenner P.

Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S21-S27. doi: 10.1016/j.parkreldis.2020.09.026. Epub 2020 Dec 19.

Can adenosine A(2A) receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?

Jenner P, Mori A, Kanda T.

Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S28-S36. doi: 10.1016/j.parkreldis.2020.09.022. Epub 2020 Dec 19.

Why target brain adenosine receptors? A historical perspective

Fredholm BB, Svenningsson P.

Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S3-S6. doi: 10.1016/j.parkreldis.2020.09.027. Epub 2020 Dec 19.

Pharmacological interactions between adenosine A(2A) receptor antagonists and different neurotransmitter systems

Pinna A, Serra M, Marongiu J, Morelli M.

Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S37-S44. doi: 10.1016/j.parkreldis.2020.10.023. Epub 2020 Dec 19.

Do caffeine and more selective adenosine A(2A) receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?

Chen JF, Schwarzschild MA.

Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1(Suppl 1):S45-S53. doi: 10.1016/j.parkreldis.2020.10.024. Epub 2020 Dec 19.

Unmet needs in Parkinson disease: Motor and non-motor

LeWitt PA, Chaudhuri KR.

Parkinsonism Relat Disord. 2020 Nov;80 Suppl 1:S7-S12. doi: 10.1016/j.parkreldis.2020.09.024. Epub 2020 Dec 19.

Recent advances in nanomaterial-modified electrical platforms for the detection of dopamine in living cells

Cho YW, Park JH, Lee KH, Lee T, Luo Z, Kim TH.

Nano Converg. 2020 Dec 22;7(1):40. doi: 10.1186/s40580-020-00250-7.

Deep Brain Stimulation of Subthalamic Nucleus in Parkinson's Disease

Samanci B, Samanci Y.

Noro Psikiyatr Ars. 2020 Nov 27;57(4):263-264. doi: 10.29399/npa.27541. eCollection 2020 Dec.

Cerebral toxoplasmosis and alcohol abuse in AIDS: dementia with multiple etiologies

de Almondes KM, Lima NC.

Dement Neuropsychol. 2020 Dec;14(4):422-429. doi: 10.1590/1980-57642020dn14-040014.

The Proprioceptive Neuromuscular Facilitation Concept in Parkinson Disease: A Systematic Review and Meta-Analysis

Alexandre de Assis IS, Luvizutto GJ, Bruno ACM, Sande de Souza LAP.

J Chiropr Med. 2020 Sep;19(3):181-187. doi: 10.1016/j.jcm.2020.07.003. Epub 2020 Dec 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias